跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
倍力腾 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Belimumab powder for concentrate for solution for infusion
Approved
生物制品
Belimumab powder for concentrate for solution for infusion
GLAXOSMITHKLINE (IRELAND) LIMITED
🇨🇳 National Medical Products Administration
Approval Date
Aug 23, 2024
Approval ID
8beaJKrdei5
Company
GLAXOSMITHKLINE (IRELAND) LIMITED
Type
生物制品
Approval Details
Approval Id
8beaJKrdei5
Approval Number
国药准字SJ20190032
Generic Name
注射用贝利尤单抗
Generic Name En
Belimumab powder for concentrate for solution for infusion
Trade Name
倍力腾
Drug Type
生物制品
Dosage Form
注射剂
Strength
120mg/瓶
Reg Date
2024-08-23
Expired Date
2029-05-23
Company Name
GLAXOSMITHKLINE (IRELAND) LIMITED
Company Detail Path
/organization/glaxosmithkline-ireland-limited
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Aug 23, 2024
Approval ID
8beaJKrdei5
Type
生物制品
Back to NMPA Approvals
